AnaptysBio, Inc.

64 articles with AnaptysBio, Inc.

• 

  AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

  3/27/2018

  Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.
• 

  4 Biotechs Ready to Kill the Market in 2018

  12/29/2017

  A look at a few biotechs which should outperform the market in 2018.
• 

  Top 5 Biotech Stocks to Buy for 2018

  12/21/2017

  A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.
• 

  The 2017 Biotech IPO Winners and Losers

  12/21/2017

  Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
• 

  4 Solid Biotechs to Load Up on This Month

  12/4/2017

  Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.

• AnaptysBio Reports Positive ANB019 Top-line Phase I Clinical Trial Results

  11/7/2017

  Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies.

• AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates

  11/7/2017

  Cash, cash equivalents and investments totaled $116.7 million as of September 30, 2017, which includes net proceeds of $80.2 million from the company’s initial public offering completed in January 2017, compared to $51.2 million as of December 31, 2016.

• AnaptysBio Announces Pricing Of Public Offering

  10/13/2017

• AnaptysBio Files Registration Statement For Proposed Public Offering

  10/11/2017

• AnaptysBio Reports Positive Topline Proof-Of-Concept Data From Phase IIa Clinical Trial Of ANB020 In Atopic Dermatitis

  10/10/2017

• AnaptysBio Announces Appointment Of J. Anthony Ware, M.D. To Board Of Directors

  8/24/2017

• AnaptysBio Announces Second Quarter 2017 Financial Results And Provides Pipeline Updates

  8/11/2017

• AnaptysBio Announces First Quarter 2017 Financial Results And Provides Pipeline Update

  5/12/2017

• AnaptysBio Release: SoCal Biotech Goes Public, Raises $75 Million

  1/26/2017

• AnaptysBio Release: Biotech Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer

  1/11/2017

• AnaptysBio Announces Clearance Of U.S. IND And U.K. CTA For ANB020

  12/13/2016

• AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results

  10/3/2016

• AnaptysBio Announces Checkpoint Receptor Agonist Antibody Portfolio

  9/26/2016

• AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial

  7/6/2016

• AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer

  4/18/2016